2-Ethyl-6-fluoronaphthalen | 55830-95-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-Ethyl-6-fluoronaphthalen
• 英文别名: 2-Ethyl-6-fluornaphthalin；2-Ethyl-6-fluoronaphthalene
• CAS: 55830-95-0
• 化学式: C₁₂H₁₁F
• 分子量: 174.218
• InChiKey: MESDVLQCZSMTCL-UHFFFAOYSA-N

物化性质

• 沸点：
  262.8±9.0 °C(Predicted)
• 密度：
  1.084±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  6-fluoro-2-acetonaphthone 在 盐酸 、 锌 作用下， 生成 2-Ethyl-6-fluoronaphthalen
  参考文献：
  名称：

  Substituent effects. XII. Substituent effects by fluorine-19 NMR

  摘要：

  DOI：

  10.1021/ja00841a034

文献信息

• BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA
  申请人：Merck Patent GmbH

  公开号：US20170210990A1

  公开（公告）日：2017-07-27

  The invention relates to bimesogenic compounds of formula I wherein R 11 , R 12 , MG 11 , MG 12 , X 11 , X 12 and Sp 1 have the meaning given in claim 1 , to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

  这项发明涉及式I的双向嵌段化合物，其中R11、R12、MG11、MG12、X11、X12和Sp1的含义如权利要求1所述，涉及在液晶介质中使用式I的双向嵌段化合物，特别涉及包括根据本发明的液晶介质的柔电液晶器件。
• SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS
  申请人：GRUNDL Marc

  公开号：US20100261687A1

  公开（公告）日：2010-10-14

  Object of the present invention are novel substituted compounds of the formula 1, wherein A, R 1 , R 2 , R 3 and R 4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

  本发明的对象是公式1的新型取代化合物，其中A、R1、R2、R3和R4的定义如描述中所述。本发明的另一个对象是提供CCR3的拮抗剂，更具体地提供包含药用可接受载体和本发明化合物中至少一种或其药用可接受盐的治疗有效量的药物组合物。
• Therapeutic methods employing substituted piperidines which are CCR3 antagonists
  申请人：GRUNDL Marc

  公开号：US20130023517A1

  公开（公告）日：2013-01-24

  Object of the present invention are novel substituted compounds of the formula 1, wherein A, R 1 , R 2 , R 3 and R 4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

  本发明的目的是提供公式1的新型取代化合物，其中A、R1、R2、R3和R4的定义如描述中所述。本发明的另一个目的是提供CCR3的拮抗剂，更具体地提供包含药学上可接受的载体和本发明化合物中至少一种或其药学上可接受的盐的治疗有效量的制药组合物。
• PHOTORESIST COMPOSITION
  申请人：MASUYAMA Tatsuro

  公开号：US20110200935A1

  公开（公告）日：2011-08-18

  The present invention provides a photoresist composition having a sulfonium salt comprising an anion represented by the formula (IA): wherein R 1 and R 2 independently represent a hydrogen atom, a C1-C12 aliphatic hydrocarbon group, a C3-C20 saturated cyclic hydrocarbon group, a C6-C20 aromatic hydrocarbon group or a C7-C21 aralkyl group, and the aliphatic hydrocarbon group, the saturated cyclic hydrocarbon group, the aromatic hydrocarbon group and the aralkyl group can have one or more substituents selected from the group consisting of a hydroxyl group, a cyano group, a fluorine atom, a trifluoromethyl group and a nitro group, and one or more —CH 2 — in the aliphatic hydrocarbon group can be replaced by —O— or —CO—, or R 1 and R 2 are bonded each other to form a C4-C20 nitrogen-containing ring together with the nitrogen atom to which they are bonded, an acrylic resin having an acid-labile group and being insoluble or poorly soluble in an aqueous alkali solution but becoming soluble in an aqueous alkali solution by the action of an acid, and an acid generator.
• INHIBITORS OF HEPATITIS C VIRUS
  申请人：Zhong Min

  公开号：US20120276051A1

  公开（公告）日：2012-11-01

  A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.